Abstract. Glioblastoma (GBM) is the most common and most aggressive primary brain tumor; the prognosis of patients with GBM remains poor. The sodium/iodide symporter (NIS) can be used to absorb several isotopes, such as 131 I for nuclear medicine imaging and radionuclide therapy. Previously, we found that the early growth response-1 (Egr1) promoter had an 131 I radiation positive feedback effect on the NIS gene. Kringle 5 (K5), a kringle domain of plasminogen, induced endothelial cell apoptosis. We investigated the effect of K5 combined with the 131 I radiation positive feedback effect (Egr1-NIS) for treating malignant U87 glioma cells using a lentiviral vector. We successfully constructed a stable U87 glioma cell line, U87-K5-Egr1-NIS. The radio-inducible Egr1 promoter induced an 131 I radiation positive feedback effect absorbed by NIS. Mediated by 131 I, K5 increased glioma cell apoptosis; 131 I radiation also increased endothelial cell sensitivity to K5-induced apoptosis. The combined therapy had a synergistic effect on the antitumor efficacy of glioma treatment, not only increasing tumor cell apoptosis but also significantly inhibiting tumor cell proliferation and reducing capillary density in U87 glioma tissues.
Introduction
Glioblastoma (GBM) is the most common and most aggressive primary brain tumor. Despite aggressive surgery, radiotherapy and chemotherapy, the prognosis of GBM remains poor. Gene therapy is increasingly being explored as a novel therapeutic option.
The sodium/iodide symporter (NIS), which facilitates iodide uptake driven by sodium ion gradients across the plasma membrane, is a simple and useful reporter. Iodine radioisotopes were first used as thyroid function tracers and subsequently for treating hyperthyroidism and benign thyroid diseases (1) . NIS can absorb several isotopes, such as 99m Tc, 188 Re and 131 I, which are important for nuclear medicine imaging and radionuclide therapy (2) (3) (4) . Therefore, as a therapeutic ectopic gene, NIS has been used in numerous preclinical studies on the treatment of a variety of cancers (5-7). Vadysirisack et al showed that the radioiodine uptake is proportionate to the total NIS protein level and that enhancing NIS protein expression improves reporter sensitivity and the therapeutic efficacy of radioiodine therapy (8) . The early growth response-1 (Egr1) promoter is a radio-inducible promoter that can be promoted by ionizing radiation (9) and induce the expression of downstream target genes. Our laboratory detected an 131 I radiation positive feedback effect in a Bac-Egr1-hNIS (a baculovirus-containing Egr1-promoted NIS) system in U87 glioma cells (10) .
Various studies have suggested that antiangiogenic drugs enhance the tumor response to radiotherapy (11) or radionuclide therapy (5, 12) . Kringle 5 (K5), a kringle domain of plasminogen, can induce apoptosis in dermal microvessel endothelial cells (ECs) (13, 14) and inhibit the proliferation of basic fibroblast growth factor-stimulated calf pulmonary arterial EC and bovine adrenal capillary ECs (14, 15) . In the present study, we constructed a stable U87 cell line expressing K5 and investigated the effect of K5 combined with the 131 I radiation positive feedback effect (Egr1-NIS) for treating malignant U87 glioma.
Materials and methods
Cell lines and animals. The U87 human glioma cell line [American Type Culture Collection (ATCC), Manassas, VA, USA] and HUVECs and the 293T cell line (Cell Bank of the Chinese Academy of Science, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin in 5% CO 2 at 37˚C. Twenty-four male BALB/c nude mice (4-weeks old) were purchased from Shanghai Slaccas Experiment Animal Corporation (Shanghai Institute for Biological Science, Shanghai, China).
Plasmid construction and lentiviral preparation. The pcDNA3.1-hNIS vector was kindly provided by Dr Sissy Jhiang (Ohio University, Athens, OH, USA). The pGL3-Egr1-Luc plasmid, containing the luciferase gene under the control of the Egr1 promoter, was a kind gift from Gerald Thiel
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I therapy mediated by sodium/iodide symporter combined with kringle 5 has a synergistic therapeutic effect on glioma (University of Saarland Medical Center, Homburg, Germany). The pET22b-K5 plasmid (His-tagged) was previously constructed in our laboratory (5) . The pLVX-CMV-Puro (puromycin) expression vector was purchased from Clontech (Takara, Dalian, China). The NIS, EGR1 and K5 (His-tagged) genes were PCR-amplified separately from pcDNA3.1-hNIS, pGL3-Egr1-Luc and pET22b-K5, respectively, and then cloned into the pLVX-CMV-Puro vector to construct pLVX-CMV-K5-Egr1-NIS, pLVX-CMV-K5-Egr1-GfP and pLVX-CMV-GfP-Egr1-NIS plasmids, respectively. The resulting plasmids were recombined with a destination vector according to the manufacturer's instructions. The viral particles were produced and amplified in 293T cells.
In vitro infection with the recombinant lentiviruses. U87 cells were infected at an multiplicity of infection (MOI) of 20 (2x10 6 pfu/10 5 cells in 1 ml complete media) with pLVX-CMV-K5-Egr1-NIS, pLVX-CMV-K5-Egr1-GfP and pLVX-CMV-GfP-Egr1-NIS, or not transduced. To generate cell lines harboring the K5-expressing antibiotic marker puromycin as controlled by the cytomegalovirus (CMV)-enhancer/promoter (NIS was controlled by the Egr1 promoter), cells were selected in 0.5 µg/ml puromycin (Sigma, Sydney, Australia) for the required duration. The stable cell lines U87-K5-NIS, U87-K5-GfP and U87-GfP-NIS were constructed.
Western blot analyses. U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cell lysates were prepared using standard methods. To detect NIS expression following 131 I irradiation, Na 131 I (final concentration, 3.7 MBq/ml) was added into the U87-K5-NIS and U87-GfP-NIS cell cultures for 24 h, and the cell lysates were obtained for western blot analysis. To detect K5 expression in the cell supernatants, western blotting was performed according to a previous study (16) . K5 and NIS proteins were separately run on 7 and 15% Tris-glycine gels, respectively. Mouse anti-NIS (Millipore, Boston, MA, USA) and mouse anti-His-tag (Abgent, Suzhou, China) antibodies were used at a 1:500 dilution at 4˚C overnight, followed by incubation with the secondary anti-mouse antibody and with peroxidase-conjugated goat anti-mouse immunoglobulin G (1:2,500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 4˚C. Anti-β-actin (1:5,000; Abgent) was used as the loading control. Immunodetection was carried out using an ECL Western Blot Detection kit (Thermo Scientific, Pierce, Waltman, MA, USA).
In vitro iodide uptake studies. We determined 125 I uptake and efflux in triplicate as previously described (17) . The day before the experiment, U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells were plated (2x10 5 cells/well) into 24-well plates. After 24 h, 500 µl HBSS containing 3.7 kBq 125 I and 10 µmol/l sodium iodide (NaI) was added. The cells were incubated at 37˚C for 5-120 min, washed twice with ice-cold HBSS and lysed using 0.5 mol/l NaOH. The radioactivity (counts/min, cpm) of the cell lysates was measured using an automatic γ-counter (Shanghai Rihuan Company, Shanghai, China).
In vitro clonogenic assay. U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells were plated on 10-cm culture dishes (6x10 6 cells/dish); 4.6 MBq 131 I in HBSS was added to each dish. After 8 h, the cells were washed three times with HBSS, trypsinized and plated into 6-well culture plates (1,000 cells/well). On day 7, the cells were stained with 1 ml crystal violet staining solution (Beyotime Institute of Biotechnology, Shanghai, China) for 10 min, and colonies containing >50 cells were counted; the results are expressed as the percentage of surviving cells. The survival rate was expressed as the percentage of colonies to that of the blank group without 131 I incubation. Data are presented as the means ± SD.
Cytotoxic effect of K5 on HUVECs in vitro.
HUVECs were plated into 6-well culture plates (5x10 5 cells/well). U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells were plated on 10-cm culture dishes (5x10 6 cells/dish). After a 24-h incubation, the U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells were washed three times with phosphate-buffered saline (PBS) and 3 ml DMEM was added to each dish. After 12 h, the medium was aspirated and centrifuged at 800 x g for 5 min. The HUVEC medium was removed, and then the centrifuged medium was added to the HUVECs. After 24 h, the HUVECs were trypsinized and plated into 6-well culture plates (500 cells/well). On day 7, the cells were stained with 1 ml crystal violet staining solution (Beyotime Institute of Biotechnology) for 10 min, and colonies containing >50 cells were counted.
Establishment of xenograft tumors in nude mice.
The right flanks of the BALB/c nude mice were s.c. injected with U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS or U87 cells in 100 µl PBS. The mice were euthanized by cervical vertebra dislocation at the end of the experiments. The animal studies were approved by the local Ethics Committee (Shanghai Jiao Tong University School of Medicine, Shanghai, China) and performed according to the principles of ethics related to animal experimentation.
Micro-single-photon emission computed tomography/ computed tomography (SPECT/CT) imaging.
To detect iodide uptake by NIS as promoted by the Egr1 promoter after iodide irradiation, three U87-K5-NIS tumor-bearing mice were i.v. injected with 18.5 MBq 125 I. Anesthesia was administered and maintained by isoflurane inhalation, and the mice were positioned spread prone and scanned using a small-animal micro-SPECT scanner (Bioscan, Washington, DC, USA) at 1 and 24 h after 125 I injection. Without moving the mice, CT images were acquired (CT dose index; CTDI = 6.1 cGy) before whole-body nanoSPECT images (10 sec/frame for systematic scans) were obtained. Two days after the first 125 I injection and microSPECT/CT imaging, U87-K5-NIS tumor-bearing mice were i.v. injected with 18.5 MBq 125 I again and microSPECT/CT imaging was performed at 1 h after the injection. The images were processed and were reconstructed using Nuclear v1.02 software; images were acquired using HiSPECT 1.4.2 software and analyzed using InVivoScope 1.44 software (all from Bioscan). Regions of interest (ROIs) were drawn around the visible organs, and the radioactivity per volume unit (Conc) in the ROIs was measured using InVivoScope 1.44.
In vivo
131 I therapy. One day before 131 I administration, the animals received a 0.5-ml i.p. injection of 0.9% NaI solution to block the thyroid uptake of any free radioactive iodide. Treatment was initiated when the tumors had grown to 3-5 mm in diameter (~70 mm 3 ). U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS or U87 tumor-bearing mice were i.v. injected with 37 MBq 131 I on day 1 and 3. Tumor size was measured on day 7 after the injection and every three days thereafter up to day 25 using calipers; tumor volume was calculated as follows:
Histology and immunohistochemistry. At 25 days after
131 I administration, the animals were sacrificed, and the tumors were cryosectioned (5 µm) and subjected to immunofluorescence and immunohistochemical analysis using mouse anti-CD31 (1:50; Dako, Glostrup, Denmark), rabbit anti-human caspase-3 (1:30; Epitomics, Burlingame, CA, USA) and rabbit anti-human Ki-67 antibodies (1:200; Thermo Scientific, fremont, CA, USA). Immunohistochemical analysis was performed using Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA). The integral optical density (IOD) of every visual field was calculated for each section. Data are represented as means ± SD. Capillary density was defined as the number of CD31 + ECs/high-power field (hpf; x200). Five hpfs were counted per section from six sections/tumor tissue in three animals/group. Statistical analysis. Data were analyzed using GraphPad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA); the means ± SD are presented. Statistical analyses were performed using two-tailed Student's t-tests for differences between groups and ANOVA for differences among groups. for all analyses, P<0.05 was considered to indicate a statistically significant result.
Results

K5 and NIS expression.
To investigate K5 and NIS expression in the U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cell lines, we detected K5 expression in the supernatant of these cell lines using western blotting. K5 was expressed in the U87-K5-NIS and U87-K5-GfP cells ( fig. 1A ) and their supernatant ( fig. 1B ), but not in the U87-GfP-NIS and U87 cells ( fig. 1A) or their supernatant (fig. 1B) . NIS was expressed in the U87-K5-NIS and U87-GfP-NIS cells but not in the U87-K5-GfP or U87 cells (fig. 1A) . Western blotting also showed weak expression of NIS protein in the U87-K5-NIS and U87-GfP-NIS cells without irradiation, but higher NIS expression after a 24-h 131 I irradiation ( fig. 1C) .
In vivo
125 I uptake in cell lines. The functional activity of NIS protein was clearly shown by its cellular iodide uptake.
125 I uptake by the U87-K5-NIS and U87-GfP-NIS cells varied with the duration of incubation. following its addition to the U87-K5-NIS and U87-GfP-NIS cells, 125 I was gradually absorbed by NIS protein and was ~6,000 cpm at 120 min; no functional iodide uptake was observed in the U87-K5-GfP and U87 cells ( fig. 2) . 125 I uptake assays. 125 I uptake by the U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells at 5-120 min.
I reduces the survival of U87 cells expressing NIS in vitro.
In vitro clonogenic assays were performed to determine the cytotoxic effect of 131 I on U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells.
131 I had a significant cytotoxic effect on the U87-K5-NIS and U87-GfP-NIS cells when compared to the effect on the U87-K5-GfP and U87 cells (P<0.001) and the control HBSS-treated U87-K5-NIS, U87-K5-GfP, U87-GfP-NIS and U87 cells (P<0.001) ( fig. 3 ).
Cytotoxic effect of K5 on HUVECs in vitro.
In vitro clonogenic assays were performed to determine the effect of K5 on HUVECs. Compared to the U87-GfP-NIS and U87 cell culture medium, the medium containing K5 secreted by the U87-K5-NIS and U87-K5-GFP cells had a significant cytotoxic effect on the HUVECs (P<0.01) (fig. 4) . 125 I biodistribution in mice bearing U87-K5-NIS xenografts. Significant radioactive uptake was observed in the U87-K5-NIS tumors at 1 h after 125 I injection (fig. 5A) ; however, 125 I uptake was not detectable in the U87-K5-NIS tumors 24 h after 125 I injection ( fig. 5B ). Two days after the first 125 I injection, the U87-K5-NIS tumorbearing mice were i.v. injected with 18.5 MBq 125 I again, and the radioactivity of the U87-K5-NIS tumors was increased significantly (Fig. 5C ). The images were processed and ROIs were created by CT positioning during SPECT imaging to define the tissues described above; the obtained Conc value was 0.1240±0.0201 µCi/mm 3 at 1 h after the first 125 I injection, which was much higher than that at 24 h after 125 I injection (0.0051±0.0002 µCi/mm 3 ) (P<0.001). Two days later at 1 h after the 125 I injection, the Conc value was 0.3243±0.0333 µCi/mm 3 , which was almost three times higher than that at 1 h after the first 125 I injection (P<0.001) (Fig. 5D ). Significant radioiodine accumulation was also observed in tissues expressing endogenous NIS, including the thyroid and stomach, and in the urinary bladder due to renal elimination ( fig. 5A-C) .
In vivo imaging of
Therapeutic effects of K5 combined with
131 I in U87 xenograft tumors expressing K5 and NIS in vivo. We initiated 131 I therapy when the tumors were 3-5 mm in diameter (~70 mm 3 ). K5 combined with 131 I significantly inhibited U87-K5-NIS tumor growth as compared to the 131 I-treated U87-GfP-NIS, U87-K5-GfP and U87 tumors (P<0.001). There was no significant difference between U87-GfP-NIS and U87-K5-GfP tumor growth (P>0.05), but these two tumors grew slowly compared with the U87 tumors (P<0.05) ( fig. 6A ). Therapy did not affect mouse food intake or physical activity. During treatment, the weight of the U87-K5-NIS tumor-bearing mice increased at almost the same rate as the U87-GfP-NIS, U87-K5-GfP and U87 tumor-bearing mice (P>0.05) ( fig. 6B ).
Immunohistochemical and immunofluorescence analysis. fig. 7A and B) . There was higher caspase-3 protein expression in the U87-GfP-NIS and U87-K5-GfP xenograft cells compared with the U87 xenograft cells (P<0.05), but the Ki-67 protein expression levels in the U87-GfP-NIS, U87-K5-GfP and U87 xenograft cells was nearly identical ( fig. 7A and B) . Immunofluorescence revealed fewer CD31 + capillaries in the U87-K5-NIS group compared with the U87-GfP-NIS (P<0.01), U87-K5-GfP (P<0.01) and U87 (P<0.001) groups. There were fewer CD31 + capillaries in the U87-K5-GfP group as compared with the U87-GfP-NIS (P<0.05) and U87 (P<0.05) groups ( fig. 7A and B) .
Discussion
We tested the hypothesis that radioiodide ( 131 I) therapy mediated by the NIS gene and the antiangiogenic agent K5 would have a synergistic effect on therapeutic antitumor efficacy in glioma. To increase the accumulation and radiotherapeutic effect of 131 I, the radio-inducible Egr1 promoter was used as the NIS gene promoter, producing an 131 I radiation positive feedback effect. The combined therapy limited glioma growth and progression more effectively. Our results indicated that the combination therapy increased tumor cell apoptosis, inhibited tumor cell proliferation and significantly reduced capillary density in the U87 glioma tissues.
Gliomas are tumors that arise from glial or glial progenitor cells in the central nervous system. The median survival time of patients with malignant glioma is <3 years (19) and is even shorter in the event of recurrence, usually 3-6 months (20) . A combination of chemotherapy or stereotactic radiosurgery with repeated surgery was previously found to improve the survival of patients with recurrent GBM compared to surgery alone, although no patient in the study survived beyond 44 weeks after treatment (21) . However, the use of radiotherapy is limited in recurrent tumors due to the associated irreversible brain tissue damage and radiation-induced necrosis of the normal brain (22) highlighting the need for new therapeutic strategies. Given the following advantages, 131 I therapy, which is mediated by the NIS gene, is used for treating thyroid cancer in the clinic.
131 I expends 971 KeV decay energy, with γ decay following rapidly after β decay. The electrons have only 0.6-2 mm tissue penetration (23) causing a low degree (24) , glioma (6) and prostate carcinoma (25) and is capable of 131 I uptake and has different inhibitory actions on tumor growth. However, intracellular iodine is rapidly released, resulting in limited radioiodide retention time within cells; therefore, 131 I therapeutic efficacy is limited. To resolve this issue, we used a radio-inducible Egr1 promoter to promote NIS expression, creating an 131 I radiation positive feedback effect to increase NIS protein expression levels, increasing the 131 I retention time and the amount in the cells. for neovascularized tumors, neovasculature-targeting therapy is a promising prospect that is aimed at destroying the blood vessels, thus depriving tumor cells of oxygen and nutrients. K5 displays its potent anti-angiogenic effect by inducing EC apoptosis (13, 14) . Moreover, inhibition of angiogenesis was observed when colorectal carcinoma cells stably expressing K5 were propagated subcutaneously in athymic nude mice (26) .
We successfully constructed the lentiviral vectors pLVX-CMV-K5-Egr1-NIS, pLVX-CMV-K5-Egr1-GfP and pLVX-CMV-GfP-Egr1-NIS, constructing the stable cell lines U87-K5-NIS, U87-K5-GfP and U87-GfP-NIS following lentiviral transduction and puromycin selection. K5 was expressed in U87-K5-NIS and U87-K5-GfP cells and their supernatant but not in U87-GfP-NIS and U87 cells or their supernatant; NIS was expressed in U87-K5-NIS and U87-GfP-NIS cells but not in U87-K5-GfP and U87 cells. There was higher NIS expression following a 24-h 131 I irradiation in U87-K5-NIS and U87-GfP-NIS cells. Guo et al reported more NIS staining by immunofluorescence testing in vitro following 131 I (7.4 MBq/ml) irradiation in Bac-Egr1-hNIS-transduced glioma cells (10) . In vivo microSPECT/CT imaging showed more significant radioactive uptake (0.3243±0.0333 µCi/mm 3 ) in U87-K5-NIS tumors two days after irradiation with 18.5 MBq 125 I as compared with U87-K5-NIS tumors without 125 I irradiation (0.1240±0.0201 µCi/mm 3 ) (P<0.001). These studies showed that the Egr1 promoter may be useful for increasing NIS protein expression and for increasing NIS radioiodide accumulation.
The in vitro clonogenic assays showed that the medium containing K5 secreted by U87-K5-NIS and U87-K5-GfP cells had a significant cytotoxic effect on HUVECs as compared to that of U87-GfP-NIS and U87 cells (P<0.05). At 25 days after 131 I administration, immunofluorescence showed a lower density of CD31 + capillaries in the U87-K5-NIS group as compared with the other three groups. Lower-density CD31 + capillaries were also observed in the U87-K5-GfP group compared with the U87-GfP-NIS (P<0.05) and U87 (P<0.05) groups. Ki-67 and caspase-3 immunohistochemical analysis revealed significantly fewer proliferating cells and increased apoptosis following 131 I treatment in U87-K5-NIS tumors as compared to the other three groups. K5 combined with 131 I significantly inhibited U87-K5-NIS tumor growth. These results showed that NIS-mediated 131 I irradiation therapy combined with K5 gene therapy was superior to single-gene therapy alone. Not only did NIS-mediated 131 I irradiation increase EC sensitivity to K5-induced apoptosis, K5 increased the 131 I-mediated glioma cell apoptosis. There are various limitations to the present study. first, although lentiviral vectors can infect both non-dividing and dividing cells (27) , induce long-term expression of transgenes and lack antigenicity (28, 29) , genetic modification with lentiviral vectors in general and stable integration of the therapeutic gene into the host cell genome raise concerns regarding personal or environmental safety (30) . Second, we constructed stable cell lines to study the efficacy of the combined gene therapy, which did not conform to clinical treatment. In the clinic, viruses are injected directly or i.v. into tumors. Therefore, tumor-specific promoters in vivo are advantageous due to their lower sensitivity to promoter inactivation and lower risk of activating the host cell defense machinery (31) . Previously, we showed that NIS expression under the human telomerase reverse transcriptase (hTERT) promoter was similar to that under the CMV promoter and that the hTERT promoter may have not only specificity but also relatively strong transcriptional activity for targeted gene expression (5) .
In conclusion, the Egr1 promoter induced an 131 I radiation positive feedback effect mediated by NIS. K5 increased 131 I-mediated glioma cell apoptosis; 131 I irradiation also increased EC sensitivity to K5-induced apoptosis. This combined gene therapy had a synergistic effect on therapeutic antitumor efficacy in glioma, inhibiting U87 cell proliferation, arresting angiogenesis and retarding U87 tumor growth more effectively than single-gene therapy alone.
